Business Standard

Dishman Pharma hits all-time high on USFDA nod to cancer drug

Reacting to the development, the stock rallied as much as 20% to Rs 278

pharma
Premium

SI Reporter New Delhi
Shares of Dishman Pharmaceuticals and Chemicals hit its record high and was locked in upper circuit on news reports that the company's partner Tesaro Inc received US Food and Drug Administration (FDA) nod for ovarian cancer drug Niraparib.

Reacting to the development, the stock rallied as much as 20% to Rs 278, its all-time high level, on the BSE.

So far nearly four lakh shares exchanged hands on the counter against its two-week average of over 1 lakh shares. 

Niraparib kills cancer cells by inhibiting production of proteins called PARPs, which help repair damaged DNA strands, reported Reuters.

"This drug has the potential to

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in